Ebola no longer incurable

PharmaTimes | August 14, 2019

A new study in the BMJ has identified two new drugs, mAb114 and REGN-EB3, that can dramatically cut mortality from Ebola, and both are being immediately offered to all patients in an effort to control the Democratic Republic of Congos DRC worst ever outbreak. The trial initially compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3, and preliminary data convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3. Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was ‘not far behind’. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%. Both drugs are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola virus, which it uses to attach itself to human cells. So far patients treated with ZMapp, the best known Ebola treatment candidate which was used in the west African epidemic of 2014, had a 49% mortality rate. Those treated with the antiviral remdesivir had a 53% mortality rate. More than 75% of those who received no treatment have died in the epidemic, which has killed nearly 1900 people out of 2831 confirmed cases.

Spotlight

This video about the information about EirGen Pharma.

Spotlight

This video about the information about EirGen Pharma.

Related News

RESEARCH

Moderna and Medison Pharma Collaborate to Commercialize Moderna's COVID-19 Vaccine in Central Eastern Europe and Israel

Moderna | June 08, 2021

Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herzegovina, Kosovo, North Macedonia, Montenegro, and Israel are among the nations included by the pact. "We are excited to work with Moderna in 20 markets, covering over 175 million people across the whole Central Eastern Europe region and in Israel," stated Meir Jakobsohn, Medison Pharma's Founder and CEO. "With Moderna's ground-breaking mRNA vaccine and Medison's international commercialization platform for highly innovative treatments, our collaboration is a perfect fit." "We value this new collaboration with Medison Pharma to ensure the successful launch of our mRNA COVID-19 vaccine," stated Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. "By delivering our vaccines in collaboration with our partners, we stay consistent in our commitment to fighting the pandemic." About Medison Pharma Medison is a global pharmaceutical company that focuses on commercializing highly innovative therapies in international markets. Medison offers a full range of integrated services for companies looking to establish a presence in international markets, drawing on a 25-year track record and collaborations with major biotech companies. Medison also has a corporate venture arm with a dedicated research and evaluation team with significant scientific and commercial expertise. About Moderna Moderna has evolved from a science research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant. Moderna maintains alliances with a diverse range of domestic & global government and commercial collaborators, allowing for the pursuit of both ground-breaking science and rapid manufacturing scale.

Read More

BUSINESS INSIGHTS

MHRA Expands Relationship with Commonwealth Informatics to Transform Drug Safety

Commonwealth Informatics, a Genpact company | January 25, 2022

Commonwealth Informatics, an independently-operated subsidiary of Genpact, and leading technology and services company with industry expertise in medical product safety and public health surveillance, today announced that it has expanded its relationship with the Medicines and Healthcare products Regulatory Agency, a medical regulatory body for the United Kingdom. MHRA has selected Commonwealth Informatics' state-of-the-art signal detection and signal management solution, Commonwealth Vigilance Workbench (CVW), to support the MHRA transformation of safety monitoring through a single integrated platform across all medicines, vaccines, blood components and devices. "The MHRA is looking to transform our vigilance services through new ways of working, underpinned by the technology we use and how we operate our services. We see our partnership with CVW enabling us to deliver a more responsive safety surveillance system through innovative technology." Mick Foy, Head of Pharmacovigilance Strategy at MHRA "We are delighted to have the opportunity to build on our longstanding research collaboration with the MHRA and deliver future value through greater efficiencies within signal detection," said Bill Blackwell, Commonwealth VP Safety Science Solutions. "The collaborative partnership will enable us, together with the MHRA, to bring new innovative methodologies to safety surveillance on behalf of patients." Commonwealth's solution will be implemented to perform signal detection and signal management across multiple data sources leveraging advanced automation, such as artificial intelligence, to ensure more accurate multivigilance analysis and processing. CVW is an integrated cloud-based signal management system supporting the detection, tracking and refinement of safety signals using evidence across multiple data sources. The MHRA is deploying Insife's HALOPV solution for case processing management, advanced automation, and real-time reporting and analytics. Commonwealth Informatics has partnered with Insife, to integrate CVW with HALOPV and to collaboratively deploy the end-to-end multi-vigilance platform in Q2 2022. Insife, headquartered in Denmark, offers specialist consulting services in multivigilance (Medicines and Devices), Regulatory Affairs (RA), and Information Technology (IT) implementation. Insife's services are based on expertise across the life sciences value chain with an understanding of digital transformation and drug safety assurance through process optimisation and automation. About Commonwealth Informatics Commonwealth Informatics is a technology and services company with industry expertise in medical product safety and public health surveillance. Pharmaceutical and biotechnology companies, government agencies, and healthcare providers use Commonwealth's products and services to assemble relevant data and answer complex clinical and safety analysis questions quickly and accurately. Commonwealth is an independently-operated subsidiary of Genpact, a global professional services firm focused on delivering digital transformation. About Medicines and Healthcare products Regulatory Agency MHRA, based in London, is an executive agency sponsored by the Department of Health and Social Care, that regulates medicines, medical devices and blood components for transfusion in the United Kingdom. Recognised globally as an authority in its field, the agency plays a leading role in protecting and improving public health and supports innovation through scientific research and development.

Read More

Aphria, ODI Pharma execute supply agreement

ODI Pharma | November 03, 2020

ODI Pharma AB today announced that, despite COVID 19 delays, it has streamlined its supply chain and executed a Supply Agreement (the "Supply Agreement") with Aphria Inc.'s ("Aphria") (TSX: APHA) (Nasdaq: APHA) wholly-owned German subsidiary, CC Pharma GmbH ("CC Pharma"). The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward. The highlights of the Supply Agreement are: The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names; The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland. Aphria Inc. Chief Executive Officer and Chairman, Irwin D. Simon comments "We are pleased to announce our partnership with ODI Pharma, which expands the international presence of our Aphria medical brand into Poland. This partnership is further evidence of our global commitment to provide patients with access to high-quality medical cannabis products as well as a testament to the strength and quality of our medical brand, Aphria. We look forward to working with ODI Pharma in bringing our high-quality medical cannabis products to patients in Poland." ODI Pharma AB CEO Derek Simmross comments "We are pleased to continue our relationship with Aphria through our new partnership between CC Pharma and ODI Pharma. We see that this will contribute to our operational efficiency and it is exciting to further advance the terms of our relationship to include a broader product offering. Our goal remains to represent the best and most technologically advanced producer of medical cannabis in the industry for the Polish people." ODI Pharma AB Chairman Volker Wiederrich comments "We are proud of our partnership with CC pharma, a global leader who shares with us the same quality values and commitments of meeting patients' needs and improving their quality of life. Also, this is another vote of confidence in ODI Pharma's leadership and the Polish medical cannabis market." About ODI Pharma AB ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. ODI will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals. About Aphria Inc. Aphria Inc. is a leading global cannabis company inspiring and empowering the worldwide community to live their very best life. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. Aphria's portfolio of brands is grounded in expertly researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders' multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.

Read More